Clinical trials: Infusion Rates
Infliximab, Infusion
Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease
OBJECTIVES OF THE STUDY 1. Investigate whether there are just as few infusion reactions with infliximab infusions of 60 min and 30 min. 2. Investigate patient and nurse satisfaction with infusions of 60 min and 30 min. 3.
- Conditions
- Infliximab, Infusion, IBD (Inflammatory Bowel Disease), Patient Satisfaction
- Trial name
- iRAPID (NCT06839820)
- Testing
- Infusion rate of infliximab
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- University Hospital, Akershus
Sleep Breathing Disorders, Tonsillitis
Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Tonsillectomy or Adeno-tonsillectomy in Children
Postoperative pain following tonsillectomy or adeno-tonsillectomy in children is severe and sometimes last for days. Sufentanil is used by epidural route for postoperative analgesia in children.
- Conditions
- Sleep Breathing Disorders, Tonsillitis, Adenoid Hypertrophy
- Trial name
- NCT02205580
- Testing
- continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion, continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion, continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jin Ni
Healthy
A Comparison of the Pharmacokinetics, Safety and Tolerance of Two Formulations of a Liquid IVIg in Healthy Volunteers
The main object of the study is to compare the AUC0-84, of a single intravenous infusion of Vigam® Liquid (infused at the licensed rate of up to 3mL/min) with Gammaplex® (infused at up to 3mL/min and up to 6mL/min).
- Trial name
- NCT02246855
- Testing
- Gammaplex® (Human Normal Immunoglobulin)
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bio Products Laboratory
Low Birth Weight
Tolerance of Increased Infusion Rates of Intravenous Fat Emulsions in Very Low Birth Weight Infants
This study was completed in October 2006. No further participates are being recruited.
- Trial name
- NCT00702767
- Testing
- INTRALIPIDS
- Volunteers
- 110 people
- Sponsor
- OSF Healthcare System
Pain, Postoperative, Postoperative Nausea and Vomiting
Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery
There will be two groups in this study: one group will be given the standard infusion of naloxone, a drug which helps reduce side effects from opioids needed after surgery, and the other group will receive a higher dose.
- Conditions
- Pain, Postoperative, Postoperative Nausea and Vomiting, Scoliosis
- Trial name
- NCT01531439
- Testing
- Naloxone
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Children's Mercy Hospital Kansas City
Hypertriglyceridemia, Hyperglycemia
Intravenous Fat Emulsions and Premature Infants
The purpose of this study is to study the tolerances of Extremely Low Birthweight Infants who are born at less than 750 grams who are started at a higher infusion rate of intravenous lipid emulsions (2 gm/kg/day).
- Trial name
- NCT01096446
- Testing
- Intravenous Fat Emulsions
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OSF Healthcare System
Primary Immunodeficiency Disease
High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)
This was a prospective, open-label, non-controlled, non-randomized multicenter Phase III study of 2 multiple-dose intravenous NewGam regimens (every 3 weeks or every 4 weeks, continuing the patient's infusion interval in the main…
- Trial name
- NGAM-05 (NCT01313507)
- Testing
- NewGam
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Octapharma
Purpura, Thrombocytopenic, Idiopathic
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatograph Purified (IGIV-C) is similar when infused at two different infusion rates.
- Trial name
- NCT00220727
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Grifols Therapeutics LLC
Congenital Hyperinsulinism
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent…
- Trial name
- NCT02937558
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Xeris Pharmaceuticals